Drug Trial Radar · NCT07917468
Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Nov 25, 2026
Primary completion
Mar 25, 2030
Study completion Nov 24, 2031
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, controlled, Phase III clinical study to evaluate the efficacy and safety of sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy, which is planned to enroll 500 subjects with locally advanced rectal cancer.
Conditions
- Locally Advanced Rectal Cancer
Interventions
OxaliplatinDrug
130 mg/m²,IV,Q3W
PlaceboDrug
20 ml D1 IV Q3W
radiotherapyRadiation
PTV1 50 Gy/25 times, PTV2 45 Gy/25 times, 5 days a week, for a total of 5 weeks (D1-D35)
CapecitabineDrug
825 mg/m ² PO BID ,Days 1-5 QW;1000mg/m ² PO BID ,Days 1-14 Q3W;
Radical resection of rectal cancerProcedure
Radical resection of rectal cancer
SintilimabDrug
200 mg D1 IV Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- EFSTime frame: throutg treatment completion an average of 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.